Inclusion criteria:
Aged 18 to 75 years
Being able to fully understand the study processes and understand the explanations of the facilitators correctly
Being able to fully understand the study processes and understand the explanations of the facilitators correctly
Being able to understand the contents of the informed consent form and sign it before entering the study
Allowing the researchers to access medical records and test results if hospitalized due to suspected, or confirmed COVID-19
Using effective methods of contraception during the study at least two months after the second dose of vaccine
Volunteers who agree not to donate blood, blood products, or bone marrow from the start of the vaccine until 21 days after receiving the last dose of the vaccine
Exclusion criteria:
Confirmed, suspected, or asymptomatic COVID-19 detected by PCR at baseline
History of contact with a person with SARS-CoV-2 infection (positive PCR test) during the last 14 days
History of SARS-CoV-2 infection (Only in immunogenicity subsample
Fever or at least two of these symptoms: Dry cough, severe fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, dyspnea, and shortness of breath during the 14 days prior to vaccination
History of severe allergic reaction to vaccination or allergic reactions to Inactivated vaccine components
Known case of tuberculosis, hepatitis B or hepatitis C
History of coagulopathy
History of splenectomy
Uncontrolled hypertension, uncontrolled diabetes, uncontrolled chronic cardiac, renal, neurologic, or severe pulmonary disease
Acute diseases or an exacerbation of a chronic disease in the last 7 days
Any malignancy, immunodeficiency, HIV, lymphoma, leukemia, or other autoimmune diseases
Receiving immunomodulators or immunosuppressors at least 14 days in the past 3 months or planning to use in the next year
Receiving live vaccine in one month or other vaccines in 14 days before inoculation
History of drug or alcohol abuse in the last 12 months caused medical, familial or occupational problems
Receiving immunoglobulins or blood products in 3 months before inoculation or planning to use in the next year
Receiving any other investigational drug in 6 months before inoculation
Having a plan to participate in a drug trial during the study period
Planning to receive any vaccination in on month after inoculation
History of severe mental disorders affecting the participation in the study
Pregnant or lactating women or those who intend to become pregnant during the study period
History of travel abroad in the last 14 days
Any other condition that makes a person inappropriate for participation based on the investigator opinion